drugset
drugset / Trial / NCT03980080

Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of OSE-127 in Healthy Subjects

NCT03980080 ↗

Phase 1 Completed 63 enrolled OSE Immunotherapeutics Servier · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a first-in-human phase I randomised, double-blind, placebo-controlled, evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single (IV and SC) and Multiple (IV only) Ascending Doses of OSE-127 in Healthy Subjects.

Timeline

Start
2018-12-19
Primary completion
2019-11-04
Completion
2019-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LUSVERTIKIMAB Monoclonal antibody — Intravenous

Indications

No indication recorded.